OLMA — Olema Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1750284 ·
Last close
$7.82
Market Cap
$684.23M
52W High
$36.26
52W Low
$6.65
ADV30
1,155,732
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -67,179,000 | -63,200,000 | 486,578,000 | 48,599,000 | 56,014,000 |
| Mar 2026 | 0 | — | -57,986,000 | -53,089,000 | 530,645,000 | 52,547,000 | 50,167,000 |
| Dec 2025 | 0 | — | -50,084,000 | -46,061,000 | 533,430,000 | 48,301,000 | 54,871,000 |
| Sep 2025 | 0 | — | -45,877,000 | -42,217,000 | 352,453,000 | 35,260,000 | 44,965,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-148,724,000
Investing CF
$-106,148,000
Financing CF
$256,779,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.88
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-650,646,000
Inventory
—
Receivables
$3,351,000
ST Investments
$452,800,000
EBIT TTM
$-201,811,000
Pretax Income TTM
$-185,151,000
Interest Exp TTM
—
Analysts
10
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -178,698,000 | -162,451,000 | 533,430,000 | 54,871,000 | 478,559,000 | -146,716,000 |
| Dec 2024 | 0 | -142,258,000 | -129,474,000 | 450,979,000 | 42,015,000 | 408,964,000 | -104,351,000 |
| Dec 2023 | 0 | -104,961,000 | -96,655,000 | 276,945,000 | 23,050,000 | 253,895,000 | -83,727,000 |
| Dec 2022 | 0 | -106,988,000 | -104,787,000 | 215,645,000 | 18,099,000 | 197,546,000 | -82,065,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$16,476,000
NetIncome TTM
$-185,151,000
OpCashFlow TTM
—
Assets (Latest)
$530,645,000
Forward EPS
$-2.67
Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)
max pain strike: $13.00 · spot: $7.82 · call volume: 353 · put volume: 6,154
Expected Move to 2026-12-18:
±$6.95
(88.87%) —
implied range
$0.87 –
$14.77
· ATM straddle on $8.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| WVE | Wave Life Sciences, Inc. | $683.76M | $3.47 | — |
| COLL | COLLEGIUM PHARMACEUTICAL, INC | $685.39M | $22.11 | — |
| PHAR | Pharming Group N.V. | $674.52M | $9.53 | — |
| IMMX | Immix Biopharma, Inc. | $664.60M | $9.29 | — |
| FTH | Faeth Therapeutics, Inc. | $661.77M | $25.61 | — |
News headlines (Yahoo Finance, 1h cache)
Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-10-02 20:30 · Yahoo
Olema Pharmaceuticals Shares Fall 15.1% Following AstraZeneca SERENA-4 Trial Results
2026-09-14 12:10 · Yahoo
Olema Oncology to Participate in Upcoming Investor Conferences
2026-08-31 20:30 · Yahoo
Olema Oncology Reports Second Quarter 2026 Financial and Operating Results
2026-08-10 20:01 · Yahoo
Does Olema Pharmaceuticals' (OLMA) Broad Russell Growth Inclusion Reveal a Turning Point in Its Investor Story?
2026-06-30 12:07 · Yahoo
Olema’s OP-3136 Data Draw Focus To Oncology Pipeline And Valuation Gap
2026-05-25 19:05 · Yahoo
Olema Oncology Announces Encouraging Initial Clinical Data from the Phase 1 Study of OP-3136, a KAT6 Inhibitor, at 2026 ASCO Annual Meeting
2026-05-21 21:00 · Yahoo
Olema Oncology Reports First Quarter 2026 Financial and Operating Results
2026-05-12 11:00 · Yahoo
SERD Market Set for Growth During the Forecast Period (2026-2036) as AstraZeneca's ETCAMAH Approval Accelerates Adoption of Oral SERDs | DelveInsight
2026-10-05 14:31 · Yahoo
ESR1-Mutated Metastatic Breast Cancer Market Expected to Grow Rapidly at 9.6% CAGR During the Forecast Period (2026–2036) Due to the Emergence of Novel Oral SERDs and Targeted Agents | DelveInsight
2026-05-20 17:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.